

Consensus Science, Technology and Innovation Limited

FINANCIAL STATEMENTS

for the year ended

31 May 2023



Company Registration No. 06680161

Consensus Science, Technology and Innovation Limited

COMPANY INFORMATION

DIRECTOR	Michael Watson
SECRETARY	Anthony Fitzpatrick (appointed 9 September 2022)
COMPANY NUMBER	06680161 (England & Wales)
REGISTERED OFFICE	1st Floor 35 Park Lane London W1K 1RB

Consensus Science, Technology and Innovation Limited

DIRECTOR'S REPORT

For the year ended 31 May 2023

The Director presents his report and financial statements for the year ended 31 May 2023.

PRINCIPAL ACTIVITY

The principal activity of the Company is to be a holding company for its subsidiaries that provide environmentally friendly solutions to business offset obligations.

DIRECTOR


The following director has held office since 1 June 2022:

Michael Watson

AUDITORS

In accordance with the provision of Section 1169 of the Companies Act 2006, the company being a dormant company within the meaning of the said section, Section 480 of the Companies Act 2006 shall apply and accordingly no auditors have been appointed.

On behalf of the board



Michael Watson
Director

23 February 2024

Consensus Science, Technology and Innovation Limited

DIRECTOR'S RESPONSIBILITIES IN THE PREPARATION OF FINANCIAL STATEMENTS

The Director is responsible for preparing the Director's Report and the financial statements in accordance with applicable law and regulations.

Company law requires the director to prepare financial statements for each financial year. Under that law the Director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the Director must not approve the financial statements unless he is satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing those financial statements, the Director is required to:

- a. select suitable accounting policies and then apply them consistently;
- b. make judgements and estimates that are reasonable and prudent;
- c. prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Director is responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable him to ensure that the financial statements comply with the Companies Act 2006. He is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Consensus Science, Technology and Innovation Limited

STATEMENT OF FINANCIAL POSITION

As at 31 May 2023

(Company registration No. 06680161)

	Notes	2023 £	2022 £
FIXED ASSETS			
Investments	2	100	100
CURRENT ASSETS			
Debtors due within one year	3	100	100
CREDITORS: Amounts falling due within one year	4	(100)	(100)
NET CURRENT ASSETS		-	-
TOTAL ASSETS LESS CURRENT LIABILITIES		100	100
CAPITAL AND RESERVES			
Called up share capital	5	100	100
TOTAL EQUITY	6	100	100


The Company was entitled to exemption under Section 480 of the Companies Act 2006 for the year ended 31 May 2023. No members have required the Company to obtain an audit of its financial statements for the year in question in accordance with Section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The Director acknowledges his responsibility for:

- ensuring the Company keeps accounting records that comply with Section 386 of the Companies Act 2006;
- preparing financial statements that give a true and fair view of the state of affairs of the Company as at the end of its financial year and of its profit or loss for the financial year in accordance with Section 393 and which otherwise comply with the provisions of the Companies Act relating to financial statements in so far as they are applicable to the Company.

The financial statements on pages 3 to 8 were approved by the board of directors and authorised for issue on 23 February 2024 and are signed on its behalf by:



Michael Watson
Director

Consensus Science, Technology and Innovation Limited

STATEMENT OF CHANGES IN EQUITY

For the year ended 31 May 2023

	Called up share capital £
Balance at 1 June 2021	100
Profit for the year	-
Total comprehensive income for the year	-
Balance at 31 May 2022	100
Profit for the year	-
Total comprehensive income for the year	-
Balance at 31 May 2023	100

Consensus Science, Technology and Innovation Limited

ACCOUNTING POLICIES

GENERAL INFORMATION

Consensus Science, Technology and Innovation Limited (“the Company”) is a limited company domiciled and incorporated in England and Wales, registration number 06680161. The address of the Company’s registered office and principal place of business is 1st Floor, 35 Park Lane, London W1K 1RB.

The Company’s principal activities are shown in the Directors’ Report.

BASIS OF ACCOUNTING

These financial statements have been prepared in accordance with FRS 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are presented in sterling, which is the functional currency of the Company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies are set out below.

STATEMENT OF CASH FLOWS

The Company has taken advantage of the exemption in FRS 102 Chapter 7 “Statement of Cash Flows” from the requirement to prepare a cash flow statement on the grounds that it is a small company.

PROFIT AND LOSS ACCOUNT

The Company did not trade during the year and has made neither a profit nor a loss in the year. Accordingly, no Statement of Comprehensive Income is presented as part of these financial statements.

INVESTMENTS

The Company’s investments in subsidiary undertakings are stated at cost less provision for impairments.

Consensus Science, Technology and Innovation Limited

ACCOUNTING POLICIES (CONTINUED)

FINANCIAL INSTRUMENTS

The Company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102, in full, to all of its financial instruments. Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument, and are offset only when the Company currently has a legally enforceable right to set off the recognised amounts and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include other receivables and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the financial asset is measured at the present value of the future receipts discounted at a market rate of interest.

Impairment of financial assets

Financial assets are assessed for indicators of impairment at each reporting end date. Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. The impairment loss is recognised in profit or loss.

Basic financial liabilities

Basic financial liabilities comprise loans from group companies, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest.

Equity instruments

Equity instruments issued by the Company are recorded at the fair value of the proceeds received, net of direct issue costs. The Company has only basic financial instruments and has not chosen to designate financial instruments as at fair value through profit or loss. Accordingly, the Company has taken advantage of the financial instrument disclosure exemptions provided by FRS 102 Chapter 11 'Basic Financial Instruments'.

CRITICAL ACCOUNTING ESTIMATES AND AREAS OF JUDGEMENT

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions

The Company makes estimates and assumptions concerning the future. The Director does not consider any estimates and assumptions have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

Critical areas of judgement

The Director does not consider there are critical areas of judgement that have a significant effect on the amounts recognised in the financial statements.

Consensus Science, Technology and Innovation Limited

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 May 2023

1 EMPLOYEES

There were no employees during the year apart from the director, who received no emoluments.

2 FIXED ASSET INVESTMENTS

	Shares in subsidiary undertaking £
Cost	
At 1 June 2022 and at 31 May 2023	100
Net book value	
At 31 May 2023	100
At 31 May 2022	100

Holdings of more than 20%

The company holds more than 20% of the share capital of the following company:

Company	Country of registration or incorporation	Class	Shares held %
CSTI Investments Limited	England & Wales	Ordinary	100.00

The aggregate amount of capital and reserves and the results of this undertaking for the last relevant financial year were as follows:

Company	Principal activity	Capital and reserves 2023 £	Profit/(loss) for the year 2023 £
CSTI Investments Limited	Investment in offset products	1,369,106	(36,195)

3 DEBTORS

	2023 £	2022 £
Other debtors	100	100

Consensus Science, Technology and Innovation Limited

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

for the year ended 31 May 2023

4	CREDITORS: amounts falling due within one year	2023	2022
		£	£
	Amounts owed to subsidiary undertakings	100	100

5	SHARE CAPITAL	2023	2022
		£	£
	Allotted and issued		
	Equity Shares		
	100 Ordinary Shares of £1 each	100	100

6 CONTROL

The ultimate controlling party is Mr V. Tchenguiz.

7 RELATED PARTY TRANSACTIONS

At the balance sheet date, and included within other debtors, £100 (2022: £100) was owed by Mr V Tchenguiz, the company's ultimate controlling party.